NCT01178697 is a Phase 2 clinical trial of Bevasizumab in Central Retinal Vein Occlusion, sponsored by Shahid Beheshti University of Medical Sciences.

Who is sponsoring NCT01178697?

NCT01178697 is sponsored by Shahid Beheshti University of Medical Sciences.

What drugs are being tested in NCT01178697?

Interventions in NCT01178697: Bevasizumab, Triamcinolone Acetonide.

What condition does NCT01178697 study?

NCT01178697 studies Central Retinal Vein Occlusion.

Is NCT01178697 still recruiting?

NCT01178697 is currently status unknown. Last updated 9 August 2010.

Last reviewed 2010-08-09 · How we verify

NCT01178697

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Three Injections of Intravitreal Bevasizumab Versus Two Injections of Intravitreal Triamcinolone in the Management of Branch Retinal Vein Occlusion

Status unknown Phase 2 Last updated 9 August 2010

What this trial tests

Phase 2 trial testing Bevasizumab in Central Retinal Vein Occlusion. Status unknown.

Timeline

1 January 2010

Primary endpoint
1 September 2010

1 December 2010

Quick facts

Lead sponsor	Shahid Beheshti University of Medical Sciences
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Masking	single
Primary purpose	treatment
Start date	1 January 2010
Primary completion	1 September 2010
Estimated completion	1 December 2010
Sites	1 location across Iran

Drugs / interventions tested

Bevasizumab — full drug profile →
Triamcinolone Acetonide — full drug profile →

Conditions studied

Central Retinal Vein Occlusion — all drugs for Central Retinal Vein Occlusion →

Sponsor

Shahid Beheshti University of Medical Sciences

Who can join

Eligibility, any sex, with Central Retinal Vein Occlusion.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Visual acuity
Time frame: 6 months

Sponsor's own description

This randomized clinical trial is conducted to evaluate the effect of three intravitreal injections of bevasizumab versus two intravitreal injections of triamcinolone in acute central retinal vein occlusion. The outcomes are visual acuity and central macular thickness. The follow-up time is 6 months.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

A systematic review and meta-analysis of the effect of intravitreal VEGF inhibitors on cardiorenal outcomes.
Lees JS, Dobbin SJH, Elyan BMP, Gilmour DF, et al · · 2023 · cited 12× · PMID 36318455 · DOI 10.1093/ndt/gfac305
The efficacy and safety of intraocular anti-VEGF injections versus anti-VEGF combined with steroids or steroid monotherapy for macular edema secondary to retinal vein occlusion: a systematic review and meta-analysis of randomized controlled trials.
Cai H, Tian M, Huang Z, Wang B. · · 2025 · PMID 41601793 · DOI 10.3389/fmed.2025.1727801

Verify or expand the search:

Other recruiting trials for Central Retinal Vein Occlusion

Currently open trials in the same condition.

NCT05476926 — A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products · active not recruiting

Other Shahid Beheshti University of Medical Sciences trials

Trials by the same sponsor.

NCT07005687 — Using MSCs for Chronic Active Antibody Mediated Rejection · NA · not yet recruiting
NCT07435558 — Homogeneous vs. Heterogeneous Learning Style Grouping in Problem-Based Learning Among Nurses · NA · not yet recruiting
NCT07408492 — Impact of AI-Based Research Training on Nursing Students · NA · not yet recruiting
NCT07176663 — Efficacy and Safety of Tirzepatide (Spartina) in Chronic Kidney Failure · NA · not yet recruiting
NCT07291622 — Synchrony-Optimized Non-Invasive Ventilation Education Program and ICU Patients · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01178697 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shahid Beheshti University of Medical Sciences
Last refreshed: 9 August 2010

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01178697.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing